Effect of Liraglutide on Cardiovascular Endpoints in Diabetes Mellitus Type 2 Patients of South Asian Descent

NCT02660047 on ClinicalTrials.gov · last registry update 2018-03-21

Finished 9 March 2018, after enrolling 51 people. Primary outcome, as filed: Stroke volume. liraglutide is approved in the US, but not for mash nafld and metabolic syndrome — a registration here is not an approval, and most drugs tested in a new condition never get one for it.

Status: COMPLETED
Phase: P4
Drug: liraglutide
Saxenda, Victoza, Xultophy
Sponsor: Leiden University Medical Center
Sponsor type: Other
Enrollment: 51
Started: 2015-08
Primary completion: 2018-03-09 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Stroke volume

Conditions studied

Diabetes Mellitus Type 2 · Metabolic Syndrome · Cardiovascular Disease · Diastolic Dysfunction · Fatty Liver

Every field above is taken directly from the registry record. See all detected changes across the class, or the liraglutide page for this molecule’s full trial and approval history.